IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy

Molinier-Frenkel, 2017, Immunosuppressive enzymes in the tumor microenvironment, FEBS Lett., 591, 3135, 10.1002/1873-3468.12784 Sun, 2020, Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment, Acta Pharmacol. Sin., 41, 970, 10.1038/s41401-020-0424-4 Tie, 2022, Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets, J. Hematol. Oncol., 15, 61, 10.1186/s13045-022-01282-8 Sikalidis, 2015, Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer?, Pathol. Oncol. Res., 21, 9, 10.1007/s12253-014-9860-0 Wei, 2021, Metabolism of amino acids in cancer, Front. Cell Develop. Biol., 8, 603837, 10.3389/fcell.2020.603837 Ma, 2019, Overexpression of Arginase-1 is an indicator of poor prognosis in patients with colorectal cancer, Pathol.-Res. Pract., 215, 152383, 10.1016/j.prp.2019.03.012 Du, 2022, Arginase: mechanisms and clinical application in hematologic malignancy, Front. Oncol., 12, 10.3389/fonc.2022.905893 Grzywa, 2020, Myeloid cell-derived arginase in cancer immune response, Front. Immunol., 11, 938, 10.3389/fimmu.2020.00938 Zhai, 2020, Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies, Front. Immunol., 11, 1185, 10.3389/fimmu.2020.01185 King, 2007, Molecules in focus: indoleamine 2, 3-dioxygenase, Int. J. Biochem. Cell Biol., 39, 2167, 10.1016/j.biocel.2007.01.004 Mbongue, 2015, The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity, Vaccines, 3, 703, 10.3390/vaccines3030703 Vannini, 2015, The dual role of iNOS in cancer, Redox Biol., 6, 334, 10.1016/j.redox.2015.08.009 Granados-Principal, 2015, Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer, Breast Cancer Res., 17, 1, 10.1186/s13058-015-0527-x Rath, 2014, Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages, Front. Immunol., 5, 532, 10.3389/fimmu.2014.00532 Burney, 1999, The chemistry of DNA damage from nitric oxide and peroxynitrite, Mutat. Res./Fund. Mol. Mech. Mutagenesis, 424, 37, 10.1016/S0027-5107(99)00006-8 Won, 2022, Guided bone regeneration with a nitric-oxide releasing polymer inducing angiogenesis and osteogenesis in critical-sized bone defects, Macromol. Biosci., 22, 10.1002/mabi.202200162 Capietto, 2022, Peroxynitrite promotes immune evasion by reducing tumor antigenicity, Cell Reports Med., 3, 100787, 10.1016/j.xcrm.2022.100787 Feng, 2018, Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers, Proc. Natl. Acad. Sci., 115, 10094, 10.1073/pnas.1800695115 Wang, 2020, Amino acids and their transporters in T cell immunity and cancer therapy, Mol. Cell, 80, 384, 10.1016/j.molcel.2020.09.006 Timosenko, 2017, Modulation of cancer-specific immune responses by amino acid degrading enzymes, Immunotherapy, 9, 83, 10.2217/imt-2016-0118 Castellano, 2020, Control of T-cell activation and signaling by amino-acid catabolizing enzymes, Front. Cell Develop. Biol., 8, 613416, 10.3389/fcell.2020.613416 Qian, 2016, IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery, RSC Adv., 6, 7575, 10.1039/C5RA25046C Moon, 2015, Targeting the indoleamine 2, 3-dioxygenase pathway in cancer, J. Immunother. Cancer, 3, 51, 10.1186/s40425-015-0094-9 Song, 2021, Indoleamine 2, 3-dioxygenase 1: a promising therapeutic target in malignant tumor, Front. Immunol., 12, 10.3389/fimmu.2021.800630 Mándi, 2012, The kynurenine system and immunoregulation, J. Neural Transm., 119, 197, 10.1007/s00702-011-0681-y Amobi, 2017, Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression, Tumor Immune Microenviron. Cancer Progr. Cancer Therapy, 129 Platten, 2012, Tryptophan catabolism in cancer: beyond IDO and tryptophan DepletionTryptophan catabolism in Cancer, Cancer Res., 72, 5435, 10.1158/0008-5472.CAN-12-0569 Mautino, 2013, NLG919, a novel indoleamine-2, 3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy, Cancer Res., 73, 491, 10.1158/1538-7445.AM2013-491 Metz, 2012, IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan, Oncoimmunology, 1, 1460, 10.4161/onci.21716 Han, 2020, Modularly designed peptide nanoprodrug augments antitumor immunity of PD-L1 checkpoint blockade by targeting indoleamine 2, 3-dioxygenase, J. Am. Chem. Soc., 142, 2490, 10.1021/jacs.9b12232 Chen, 2016, An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy, Nat. Commun., 7, 1, 10.1038/ncomms13443 Peng, 2018, Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy, Adv. Sci., 5, 1700891, 10.1002/advs.201700891 Guo, 2021, Indoleamine 2, 3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy, Biomaterials, 276, 121018, 10.1016/j.biomaterials.2021.121018 Jung, 2021, Phenylboronic acid-based core–shell drug delivery platform clasping 1, 3-dicarbonyl compounds by a coordinate interaction, Biomater. Sci., 9, 6851, 10.1039/D1BM01169C Saravanakumar, 2020, Polymersomes with singlet oxygen-labile poly (β-aminoacrylate) membrane for NIR light-controlled combined chemo-phototherapy, J. Control. Release, 327, 627, 10.1016/j.jconrel.2020.09.010 Stylianopoulos, 2013, EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors, Ther. Deliv., 4, 421, 10.4155/tde.13.8 Subhan, 2021, Recent advances in tumor targeting via EPR effect for cancer treatment, J. Personal. Med., 11, 571, 10.3390/jpm11060571 Park, 2021, Enzyme-triggered disassembly of polymeric micelles by controlled depolymerization via cascade cyclization for anticancer drug delivery, ACS Appl. Mater. Interfaces, 13, 8060, 10.1021/acsami.0c22644 Tan, 2021, Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models, Biomaterials, 277, 121061, 10.1016/j.biomaterials.2021.121061 Harnoy, 2014, Enzyme-responsive amphiphilic PEG-dendron hybrids and their assembly into smart micellar nanocarriers, J. Am. Chem. Soc., 136, 7531, 10.1021/ja413036q Li, 2020, Enzyme-responsive nanoparticles for anti-tumor drug delivery, Front. Chem., 8, 647, 10.3389/fchem.2020.00647 Seok, 2018, Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR), J. Biol. Chem., 293, 1994, 10.1074/jbc.RA117.000631 Xiang, 2009, Homogeneous graft copolymerization and characterization of novel artificial glycoprotein: chitosan-poly (L-tryptophan) copolymers with secondary structural side chains, J. Polym. Sci. A Polym. Chem., 47, 925, 10.1002/pola.23211 Wang, 2016, Dual-responsive star-shaped polypeptides for drug delivery, RSC Adv., 6, 6368, 10.1039/C5RA20972B Chen, 2022, Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells, Biochem. Pharmacol., 197, 114940, 10.1016/j.bcp.2022.114940 Yang, 2021, The IFN-γ-IDO1-kynureine pathway-induced autophagy in cervical cancer cell promotes phagocytosis of macrophage, Int. J. Biol. Sci., 17, 339, 10.7150/ijbs.51241 Oh, 2020, Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells, J. Clin. Invest., 130, 3865, 10.1172/JCI131859 Lan, 2020, Codelivered chemotherapeutic doxorubicin via a dual-functional immunostimulatory polymeric prodrug for breast cancer immunochemotherapy, ACS Appl. Mater. Interfaces, 12, 31904, 10.1021/acsami.0c06120 Zhang, 2021, Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy, Nat. Commun., 12, 2934, 10.1038/s41467-021-23194-w